Sangamo Therapeutics, Inc.

Sangamo Biosciences, Inc.

Dow Agrosciences LLC

The University of Texas System

University of California

Corteva Agriscience LLC

Jeffrey C. Miller

Lei Zhang

Jeffrey C Miller

Edward J Rebar

Fyodor Urnov

David Paschon

Philip D Gregory

Michael C Holmes

Dmitry Y Guschin

Steven Robert Webb

Joseph F Petolino

Yannick Doyon

Manju Gupta

H Steve Zhang

Siyuan Tan

German Carlos Spangenberg

Gregory J Cost

W Michael Ainley

Matthew Hayden

Tim Sawbridge

Andreas Reik

Trevor Collingwood

William M Ainley

Matthew J Henry

John White Forster

Noel Cogan

Robbi J Garrison

Qihua C Cai

Carl O Pabo

Russell DeKelver

Sarah E Worden

Stephen N Novak

Laurence J N Cooper

Nicole Arnold

Vipula Shukla

Jon Christopher Mitchell

Ryan C Blue

Lisa W Baker

Steven R Webb

Noriyuki Kasahara

Jayakumar Pon Samuel

Jianbin Wang

Guofu Li

Andrew F Worden

Pei-Qi Liu

Thomas Wechsler

Beth C Rubin-Wilson

Bryan Zeitler

Yidong Ran

Steven Froelich

John Mason

Josee Laganiere

Lisa L Schulenberg

Daniel Isenegger

Laurence Jn Cooper

Ivan Krivega

Friedrich Fauser

Pon Samuel

William Michael Ainley

John Forster

German Spangenberg

Dmitry Guschin

Dmitry J Guschin

Laurence J Cooper

Russell Dekelver

Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases with alternative configurations. Also described are methods of making and using compositions comprising these linkers.

Compositions for linking DNA-binding domains and cleavage domains

The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic cell.

Regulation of gene expression using engineered nucleases

Described herein are DNA-editing complexes, particularly DNA-editing complexes that specifically alter a single base pair in target DNA sequence as well as methods of making and using these DNA-editing complexes.

Engineered target specific base editors

Described herein are engineered nucleases comprising mutations in the cleavage domain (e.g., FokI or homologue thereof) and/or DNA binding domain (zinc finger protein, TALE, single guide RNA) such that on-target specificity is increased.

Engineered target specific nucleases

Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.

Artificial nucleases comprising engineered cleavage half-domains

Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.

Methods and compositions for treating Huntington's Disease

Disclosed herein are polypeptides, polynucleotides encoding, cells and organisms comprising novel DNA-binding domains, including TALE DNA-binding domains. Also disclosed are methods of using these novel DNA-binding domains for modulation of gene expression and/or genomic editing of endogenous cellular sequences.

DNA-binding proteins and uses thereof

Disclosed herein are methods and compositions for insertion of transgene sequences encoding proteins involved in clotting into the genome of a cell for treating conditions including hemophilias.

Methods and compositions for treating hemophilia

Disclosed herein are compositions for linking DNA binding domains and cleavage domains (or cleavage half-domains) to form non-naturally occurring nucleases. Also described are methods of making and using compositions comprising these linkers.

Methods and compositions for a genetic disease are provided.

Methods and compositions for treatment of a genetic condition

Disclosed herein are methods and compositions for parallel or sequential transgene stacking in plants to produce plants with selected phenotypes.

Methods and compositions for integration of an exogenous sequence within the genome of plants

Artifical nucleases comprising engineered cleavage half-domains

Disclosed herein are Htt repressors and methods and compositions for use of these Htt repressors.

Htt repressors and uses thereof

Growing community of inventors

Richmond, CA, United States of America

Jeffrey C Miller